Akorn announced the appointment of its new Board of Directors. Akorn's new board members are: Robert Webster (Chair), Co-Founder and Senior Managing Director at Twin Haven Capital, who has over 30 years of diverse financial, transactional and business leadership experience including having served on or chaired fifteen corporate boards across an array of industries. Douglas Boothe, President and Chief Executive Officer of Akorn, who has 20 years of pharma experience, leading and building businesses and executing operational turnarounds, including roles at Impax, Perrigo, Actavis and Alpharma. Kevin Bain, retired former CFO of Alvotech and Alvogen, who has over 40 years of financial operations and general management experience, including over 20 years in the Johnson & Johnson Family of Companies. James Bauersmith, Chief Strategy Officer and General Counsel of ByHeart, who has over 15 years of experience in product development, mergers & acquisitions, and legal matters in the pharmaceutical industry, including roles at Amneal, Fresenius and Teva. Elizabeth Jeffords, Chief Commercial & Strategy officer at Alkahest, who has over 20 years of commercial, development, quality and operations experience in ophthalmology, oncology, immunology, and infectious disease, including roles at Roche and Genentech. The new board appointments follow the completion of the sale of Akorn on October 1, 2020. Akorn is now operating as a private entity under the legal name Akorn Operating Company LLC.